Source: JD Supra

Organizations in healthcare and life sciences face significant regulatory and privacy exposure when AI is embedded in their operations, and vendor contracts that are silent on AI can undermine compliance frameworks and patient safety. AI learns from data and generative AI produces novel content, which raises distinct legal, contractual, and governance concerns given its reliance on vast training datasets. Despite regulatory developments such as the EU AI Act and a growing body of U.S. state laws, many vendor agreements remain silent on AI; the piece warns that broad data-use clauses can function as open-ended training rights and that vendor assertions that data is “de-identified” may not meet HIPAA’s demanding standard. The text emphasizes that AI models trained on clinical trial data, genomic information, or patient health records may be subject to HIPAA, state health privacy laws, consumer protection rules, and FDA data integrity requirements, and that improper use can trigger fines, enforcement, or compromise trial integrity.

The analysis also highlights third-party infrastructure risks, noting that changes in hosting providers or foundation models such as GPT-4, Claude 3, or Gemini can materially affect security, privacy, and performance without customer notice. Standard warranty and liability language often fails to address AI-specific harms, so organizations should negotiate AI-specific warranties covering compliance with applicable laws, avoidance of bias and discrimination, and protection of third-party intellectual property rights. Indemnification provisions should explicitly cover AI-related claims including privacy violations, erroneous outputs, and copyright infringement, while limitation of liability clauses (caps and exclusions of indirect damages) should be scrutinized because they can leave organizations without recourse for regulatory fines, breach notification costs, and reputational harm. The piece concludes by framing appropriate contract provisions as strategic for regulatory compliance, patient safety, IP protection, and defending innovations, and it includes a general disclaimer that the information is not a substitute for tailored legal advice.